These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22972823)

  • 1. Production of KPC-2 alone does not always result in β-lactam MICs representing resistance in gram-negative pathogens.
    Roth AL; Thomson KS; Lister PD; Hanson ND
    J Clin Microbiol; 2012 Dec; 50(12):4183-4. PubMed ID: 22972823
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of gram-negative β-lactamase producing pathogens in the clinical lab.
    Thomson KS
    Curr Pharm Des; 2013; 19(2):250-6. PubMed ID: 22894616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative evolution of mechanisms of beta-lactam resistance.
    Medeiros AA
    Clin Microbiol Infect; 2000; 6 Suppl 3():27-33. PubMed ID: 11449645
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging epidemic of metallo-beta-lactamase-mediated resistances.
    Jones RN; Biedenbach DJ; Sader HS; Fritsche TR; Toleman MA; Walsh TR
    Diagn Microbiol Infect Dis; 2005 Feb; 51(2):77-84. PubMed ID: 15698711
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
    Livermore DM; Mushtaq S; Warner M; Woodford N
    J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-lactam susceptibility in extended-spectrum β-lactamase-producing isolates.
    Agrawal GN; Rahangdale HD; Walawalkar AW
    Indian J Pathol Microbiol; 2017; 60(1):142-143. PubMed ID: 28195120
    [No Abstract]   [Full Text] [Related]  

  • 7. Extended-spectrum beta-lactamases: a brief clinical update.
    Malloy AM; Campos JM
    Pediatr Infect Dis J; 2011 Dec; 30(12):1092-3. PubMed ID: 22105419
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of a DNA microarray, the check-points ESBL/KPC array, for rapid detection of TEM, SHV, and CTX-M extended-spectrum beta-lactamases and KPC carbapenemases.
    Naas T; Cuzon G; Truong H; Bernabeu S; Nordmann P
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3086-92. PubMed ID: 20547813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!
    Thomson JM; Bonomo RA
    Curr Opin Microbiol; 2005 Oct; 8(5):518-24. PubMed ID: 16126451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming β-lactam resistance in Gram-negative pathogens.
    Bush K
    Future Med Chem; 2016 Jun; 8(9):921-4. PubMed ID: 27228233
    [No Abstract]   [Full Text] [Related]  

  • 11. The new beta-lactamases.
    Jacoby GA; Munoz-Price LS
    N Engl J Med; 2005 Jan; 352(4):380-91. PubMed ID: 15673804
    [No Abstract]   [Full Text] [Related]  

  • 12. Metallo-β-lactamases: a last frontier for β-lactams?
    Cornaglia G; Giamarellou H; Rossolini GM
    Lancet Infect Dis; 2011 May; 11(5):381-93. PubMed ID: 21530894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance to beta-lactams].
    Williams D
    Antibiot Khimioter; 1997; 42(10):5-9. PubMed ID: 9412405
    [No Abstract]   [Full Text] [Related]  

  • 14. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control.
    Stürenburg E; Mack D
    J Infect; 2003 Nov; 47(4):273-95. PubMed ID: 14556752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of in vitro susceptibility tests for carbapenemase-producing Gram-negative bacteria.
    Sun J; Xu Y; Yu Y; Ni Y
    J Med Microbiol; 2015 Jun; 64(6):620-622. PubMed ID: 25873580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections.
    Rameshkumar G; Ramakrishnan R; Shivkumar C; Meenakshi R; Anitha V; Venugopal Reddy YC; Maneksha V
    Indian J Ophthalmol; 2016 Apr; 64(4):303-11. PubMed ID: 27221683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of co-expression of newer beta-lactamases (ESBLs, Amp-C-beta-lactamases, and metallo-beta-lactamases) in gram-negative bacilli.
    Chatterjee SS; Karmacharya R; Madhup SK; Gautam V; Das A; Ray P
    Indian J Med Microbiol; 2010; 28(3):267-8. PubMed ID: 20644325
    [No Abstract]   [Full Text] [Related]  

  • 19. Metallo-beta-lactamases: the quiet before the storm?
    Walsh TR; Toleman MA; Poirel L; Nordmann P
    Clin Microbiol Rev; 2005 Apr; 18(2):306-25. PubMed ID: 15831827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.